论文部分内容阅读
目的:评价液基细胞学及HPV-DNA检测在宫颈癌筛查中的价值。方法:以活检病理结果为金标准,重点观察在液基细胞学阴性且HPVDNA阴性的病人中,活检病理结果是宫颈癌的发生率(即假阴性率)。结果:在815例宫颈异常者中,HPV-DNA阳性例数497(60.98%),阴性例数318(39.02%);液基细胞细胞学良性改变80例(9.82%),ASC 358例(43.93%),LSIL227例(27.85%),HSIL131例(16.07%),宫颈癌19例(2.33%);活检病理结果宫颈急、慢性炎症491例(60.25%),CINⅠ97例(11.90%);CINⅡ/Ⅲ195例(23.93%),宫颈浸润癌32例(3.93%)。在液基细胞学阴性且HPV-DNA阴性的病人中,活检病理结果是宫颈癌的发生率(假阴性)为0.00%(1/64)。结论:液基细胞学检查与HPV-DNA联合检测,其假阴性率极低,值得作为宫颈癌的筛查方法推广。
Objective: To evaluate the value of liquid-based cytology and HPV-DNA testing in cervical cancer screening. Methods: The biopsy results were taken as the gold standard. The biopsy results were the incidence of cervical cancer (ie false negative rate) in patients with negative liquid-based cytology and negative HPVDNA. Results: Among 815 cases of cervical abnormalities, the positive cases of HPV-DNA were 497 (60.98%) and negative cases were 318 (39.02%). The benign changes of liquid-based cytology were 80 cases (9.82%), ASC 358 cases (21%), LSIL227 (27.85%), HSIL131 (16.07%) and cervical cancer in 19 cases (2.33%). The biopsy results included 491 cases (60.25%) of cervical acute and chronic inflammation, 97 cases (11.90%) of CINⅡ, Ⅲ 195 cases (23.93%), 32 cases of invasive cervical cancer (3.93%). In liquid-based cytology-negative and HPV-DNA-negative patients, the biopsy result was a cervical cancer incidence (false negative) of 0.00% (1/64). Conclusion: The combination of liquid-based cytology and HPV-DNA test has a very low false-negative rate and is worth popularizing as a screening method for cervical cancer.